Pacer Advisors Inc. Acquires 21,964 Shares of Zoetis Inc. $ZTS

Posted by Brian Himes on Jun 21st, 2026

Pacer Advisors Inc. increased its holdings in Zoetis Inc. (NYSE:ZTS – Free Report) by 18.3% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 141,883 shares of the company’s stock after acquiring an additional 21,964 shares during the period. Pacer Advisors Inc.’s holdings in Zoetis were worth $17,852,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in ZTS. RFG Advisory LLC increased its holdings in Zoetis by 4.9% during the 4th quarter. RFG Advisory LLC now owns 1,708 shares of the company’s stock worth $215,000 after purchasing an additional 80 shares in the last quarter. YANKCOM Partnership lifted its holdings in shares of Zoetis by 3.5% in the fourth quarter. YANKCOM Partnership now owns 2,402 shares of the company’s stock valued at $302,000 after purchasing an additional 81 shares in the last quarter. Beese Fulmer Investment Management Inc. lifted its holdings in shares of Zoetis by 2.4% in the third quarter. Beese Fulmer Investment Management Inc. now owns 3,672 shares of the company’s stock valued at $537,000 after purchasing an additional 85 shares in the last quarter. Quest 10 Wealth Builders Inc. boosted its position in shares of Zoetis by 4.7% during the fourth quarter. Quest 10 Wealth Builders Inc. now owns 1,904 shares of the company’s stock valued at $240,000 after buying an additional 86 shares during the last quarter. Finally, Financial Engines Advisors L.L.C. grew its holdings in Zoetis by 4.4% during the third quarter. Financial Engines Advisors L.L.C. now owns 2,043 shares of the company’s stock worth $299,000 after buying an additional 87 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Stock Down 0.0%

Shares of NYSE:ZTS opened at $78.69 on Friday. Zoetis Inc. has a 1 year low of $72.38 and a 1 year high of $161.77. The company has a market capitalization of $32.99 billion, a PE ratio of 13.05, a price-to-earnings-growth ratio of 1.23 and a beta of 0.75. The business has a fifty day moving average price of $93.01 and a two-hundred day moving average price of $112.54. The company has a debt-to-equity ratio of 2.80, a current ratio of 3.15 and a quick ratio of 1.91.

Zoetis (NYSE:ZTS – Get Free Report) last released its earnings results on Thursday, May 7th. The company reported $1.53 EPS for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). The business had revenue of $2.26 billion for the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The company’s revenue for the quarter was up 2.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.48 earnings per share. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. Analysts forecast that Zoetis Inc. will post 6.88 earnings per share for the current year.

Zoetis Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Monday, July 20th will be given a $0.53 dividend. The ex-dividend date of this dividend is Monday, July 20th. This represents a $2.12 annualized dividend and a yield of 2.7%. Zoetis’s payout ratio is currently 35.16%.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on the company. Stifel Nicolaus dropped their price objective on Zoetis from $105.00 to $95.00 and set a “hold” rating on the stock in a research note on Friday, May 22nd. Weiss Ratings downgraded shares of Zoetis from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday, June 12th. Leerink Partners reissued a “market perform” rating on shares of Zoetis in a research report on Tuesday, March 10th. Citigroup cut their price target on shares of Zoetis from $145.00 to $112.00 and set a “buy” rating on the stock in a report on Monday, May 18th. Finally, Argus reaffirmed a “hold” rating on shares of Zoetis in a research report on Wednesday, May 27th. Six equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $133.92.

Get Our Latest Stock Report on Zoetis

Insider Buying and Selling at Zoetis

In related news, Director Michael B. Mccallister bought 3,000 shares of the company’s stock in a transaction on Monday, May 11th. The shares were purchased at an average cost of $77.76 per share, for a total transaction of $233,280.00. Following the completion of the purchase, the director directly owned 24,524 shares in the company, valued at $1,906,986.24. The trade was a 13.94% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Frank A. Damelio purchased 6,650 shares of the firm’s stock in a transaction dated Wednesday, May 13th. The shares were bought at an average price of $75.39 per share, with a total value of $501,343.50. Following the purchase, the director owned 21,458 shares in the company, valued at $1,617,718.62. The trade was a 44.91% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have purchased a total of 11,650 shares of company stock worth $886,384 over the last three months. 0.22% of the stock is currently owned by insiders.

Key Headlines Impacting Zoetis

Here are the key news stories impacting Zoetis this week:

Negative Sentiment: Multiple law firms, including Rosen, The Gross Law Firm, Kessler Topaz, Bragar Eagel & Squire, and others, announced or reiterated securities class actions against Zoetis, with claims tied to alleged misstatements and omissions about product adoption during the January 14, 2025 to May 6, 2026 period. Article Title
Negative Sentiment: The lawsuits highlighted a July 27, 2026 lead-plaintiff deadline and suggested investors who bought ZTS during the class period may have suffered losses, increasing legal overhang and uncertainty for the stock. Article Title
Neutral Sentiment: Zacks noted ZTS recently outperformed the broader market, but that commentary was largely backward-looking and did not change the heavier focus on litigation headlines. Article Title

Zoetis Company Profile

(Free Report)

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.